You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Roche's CDx would help Inotrem identify suitable patients for a new therapy it's developing for septic shock, and help physicians identify patients at the highest risk of death.
Labs reported on their work with kits from both Roche and Thermo Fisher, both of which have launched new commercial liquid biopsy products in recent years.
Illumina had filed a series of suits against several companies in the UK starting in 2015, which were recently consolidated into one case.
Roche said the deal will expand its integrated-core-lab position and enable laboratories to make faster, data-driven decisions on operations and processes.
Using a blood volume of 100 μL, the test demonstrated a sensitivity of 90.2 percent for the diagnosis of blood-culture positive sepsis episodes.
The newly cleared panel has five assays — Roche's Ventana BRAF V600E assay and four other assays that target the MMR proteins MLH1, MSH2, MSH6 and PMS2.
The agreement could lead to a companion diagnostic that supports the development of an Inotrem compound in clinical trials for septic-shock treatment.
The approved Ventana ALK (D5F3) immunohistochemistry CDx is available for use on the Roche BenchMark XT or BenchMark Ultra IHC/ISH slide staining systems.
A recent study has shown that the biomarker used by the test, GDF-15, is a strong predictor of bleeding risk in patients with atrial fibrillation.
For the third quarter of 2017, Roche Diagnostics reported that its revenues rose 6 percent to CHF 2.98 billion from CHF 2.80 billion in the prior-year quarter.